YHR131C Antibody

What is YHR131C and why develop antibodies against it?

YHR131C is a gene in Saccharomyces cerevisiae S288C that encodes a hypothetical protein. It is classified as a protein-coding gene with Entrez Gene ID 856532 . As a hypothetical protein, its function remains largely uncharacterized, making it a target of interest for researchers studying yeast genetics and protein function. Developing antibodies against YHR131C provides essential tools for protein detection, localization studies, and functional characterization.

Antibodies against YHR131C enable researchers to validate the expression of this hypothetical protein, determine its subcellular localization, and identify potential interaction partners through techniques such as immunoprecipitation, Western blotting, and immunofluorescence microscopy. These investigations are crucial steps in elucidating the biological role of previously uncharacterized proteins in model organisms like yeast.

What types of antibodies are most useful for YHR131C research?

When selecting antibody types, researchers should consider:

Similar to approaches used for other antibody development , researchers may employ phage display or yeast display methods to develop high-affinity antibodies against YHR131C, particularly given the challenges of generating antibodies against hypothetical proteins.

Which regions of YHR131C are most immunogenic for antibody production?

Based on protein sequence analysis of YHR131C (NP_011999.2) , ideal epitope candidates for antibody production should focus on regions with:

• High surface probability (hydrophilic regions)

• High antigenic index

• Low sequence similarity to other yeast proteins

• Avoidance of predicted post-translational modification sites

For hypothetical proteins like YHR131C, computational prediction of immunogenic regions is particularly valuable since structural information may be limited. Both N-terminal and C-terminal regions often serve as good targets for antibody production, as they frequently have unique sequences and are more likely to be surface-exposed.

How can researchers optimize antigen design for generating YHR131C antibodies?

Optimal antigen design for YHR131C antibodies should incorporate careful sequence analysis and recombinant protein expression strategies. The complete ORF sequence of YHR131C is 2553bp , providing multiple options for antigen design.

For antigen preparation, researchers should consider:

• Full-length protein expression: Using the complete YHR131C ORF clone in an expression vector like pcDNA3.1-C-(k)DYK to produce the entire protein.

• Peptide selection: For synthetic peptide antigens, select 15-20 amino acid sequences with:

  • High antigenicity scores

  • Minimal homology to other yeast proteins

  • Avoidance of hydrophobic regions

  • Consideration of secondary structure predictions

• Expression systems: E. coli may be suitable for expressing fragments of YHR131C, while insect or mammalian cells might be better for full-length protein with proper folding.

• Purification strategy: Adding affinity tags (His-tag or GST) to facilitate purification while ensuring tags don't interfere with immunogenic epitopes.

Similar to techniques described for other antigens , combining phage display with yeast display could offer advantages in selecting high-affinity antibodies against YHR131C.

What are the optimal expression systems for producing YHR131C protein for antibody generation?

The choice of expression system significantly impacts the quality of YHR131C antigen and resulting antibodies. Consider these options:

The ORF clone of YHR131C is available in the pcDNA3.1-C-(k)DYK vector , which can be used for mammalian expression. For research purposes, expressing the protein in its native host (S. cerevisiae) may preserve authentic folding and modifications.

How should researchers validate the specificity of generated YHR131C antibodies?

Rigorous validation is essential for antibodies targeting hypothetical proteins like YHR131C. A comprehensive validation strategy should include:

• Western blot analysis:

  • Wild-type yeast versus YHR131C knockout strains

  • Detection of overexpressed tagged YHR131C protein

  • Peptide competition assays to confirm epitope specificity

• Immunoprecipitation validation:

  • Recovery of YHR131C from tagged versus untagged strains

  • Mass spectrometry confirmation of precipitated protein

• Immunofluorescence microscopy:

  • Comparison of staining patterns in wild-type versus knockout strains

  • Co-localization with tagged YHR131C protein

  • Absence of signal with pre-immune serum

• Cross-reactivity assessment:

  • Testing against related yeast proteins

  • Evaluation in different yeast strains beyond S288C

This multi-technique validation approach is similar to methods used for other antibody targets , where multiple confirmation techniques strengthen confidence in antibody specificity.

How can YHR131C antibodies be used to determine protein localization and expression levels?

YHR131C antibodies enable several advanced techniques for characterizing this hypothetical protein's expression and localization:

• Subcellular fractionation with immunoblotting:

  • Separate yeast cell components (cytosol, nucleus, mitochondria, etc.)

  • Probe fractions with YHR131C antibodies

  • Quantify relative distribution across compartments

• Quantitative immunofluorescence microscopy:

  • Co-staining with organelle markers

  • Time-course studies during cell cycle or stress conditions

  • 3D reconstruction to determine precise localization

• Flow cytometry:

  • Quantify expression levels across population

  • Compare expression under different growth conditions

  • Correlate with cell cycle phases

• Chromatin immunoprecipitation (ChIP):

  • If YHR131C has potential nuclear functions

  • Map association with specific genomic regions

  • Integrate with transcriptional data

Using approaches similar to those applied in clinical antibody research , careful quantification and statistical analysis of YHR131C expression patterns under different conditions can provide insights into this protein's function.

What protein-protein interaction studies can be performed using YHR131C antibodies?

YHR131C antibodies enable several methodologies to identify and characterize protein interaction partners:

• Co-immunoprecipitation (Co-IP):

  • Precipitate YHR131C using validated antibodies

  • Identify co-precipitating proteins via mass spectrometry

  • Confirm interactions with reverse Co-IP

• Proximity-dependent biotin identification (BioID):

  • Fuse biotin ligase to YHR131C

  • Use antibodies to confirm expression and localization

  • Identify proximal proteins through streptavidin pulldown

• Yeast two-hybrid validation:

  • Screen for interaction partners using Y2H

  • Validate interactions using Co-IP with YHR131C antibodies

  • Determine interaction domains

• In situ proximity ligation assay (PLA):

  • Visualize interactions in their native cellular context

  • Quantify interaction frequency and localization

  • Analyze changes under different conditions

These methods can help elucidate the biological function of YHR131C by placing it in a protein interaction network context, similar to approaches used in clinical research with other antibodies .

How can YHR131C antibodies help investigate post-translational modifications?

Investigating post-translational modifications (PTMs) of YHR131C requires specific approaches with custom antibodies:

• Modification-specific antibodies:

  • Develop antibodies against predicted modification sites

  • Validate using in vitro modified recombinant protein

  • Compare with general YHR131C antibodies in parallel assays

• Two-dimensional gel electrophoresis:

  • Separate YHR131C protein based on charge and mass

  • Detect isoforms using general YHR131C antibodies

  • Identify modifications by mass spectrometry

• Sequential immunoprecipitation:

  • First IP with general YHR131C antibodies

  • Second IP with modification-specific antibodies (phospho, ubiquitin, etc.)

  • Quantify modified fraction of total YHR131C pool

• In vitro modification assays:

  • Express and purify YHR131C

  • Subject to kinases, acetyltransferases, or other modifying enzymes

  • Detect modifications using specific antibodies

Drawing parallels from research on protein modifications such as tyrosine nitration in HGF , researchers can develop similar strategies to investigate potential modifications in YHR131C that might regulate its function.

What are the optimal conditions for Western blot analysis using YHR131C antibodies?

Optimizing Western blot conditions for YHR131C antibodies requires systematic testing of multiple parameters:

For proteins like YHR131C with unknown expression levels, including positive controls such as tagged overexpressed protein is crucial for interpreting results. The specificity of detection can be enhanced using approaches similar to those described for other antibody developments .

How should researchers design immunofluorescence experiments using YHR131C antibodies?

Immunofluorescence microscopy with YHR131C antibodies requires careful optimization for yeast cells:

• Cell fixation methods:

  • Compare formaldehyde (3.7%) vs. methanol fixation

  • Test with and without cell wall digestion using zymolyase

  • Optimize fixation time (15-30 minutes) to maintain structure while allowing antibody access

• Permeabilization conditions:

  • Test 0.1-0.5% Triton X-100 vs. 0.1% SDS

  • Optimize incubation time (5-15 minutes)

  • Consider detergent type based on predicted YHR131C localization

• Blocking and antibody incubation:

  • Use 3-5% BSA or normal serum matching secondary antibody species

  • Compare primary antibody dilutions (1:100-1:1000)

  • Test incubation times (1h at RT vs. overnight at 4°C)

• Controls and counterstaining:

  • Include YHR131C knockout as negative control

  • Use tagged YHR131C as positive control

  • Counterstain with DAPI for nuclear reference

  • Include organelle markers for co-localization studies

Using well-established immunofluorescence techniques adapted for yeast cells will maximize detection specificity while minimizing artifacts.

What considerations are important for co-immunoprecipitation using YHR131C antibodies?

Co-immunoprecipitation (Co-IP) with YHR131C antibodies requires optimization of multiple parameters:

• Lysis conditions:

  • Compare gentle (Tris-based, 0.1% NP-40) vs. stringent (RIPA) buffers

  • Optimize salt concentration (150-500 mM NaCl)

  • Test protease and phosphatase inhibitor combinations

  • Consider crosslinking before lysis for transient interactions

• Antibody coupling strategies:

  • Direct addition vs. pre-binding to Protein A/G beads

  • Covalent coupling to reduce antibody contamination

  • Test antibody amounts (1-10 μg per IP)

• Washing conditions:

  • Number of washes (3-5)

  • Buffer stringency gradients

  • Salt concentration effects on interaction stability

• Elution and analysis:

  • Gentle (native) vs. denaturing elution

  • Sequential elution strategies

  • Mass spectrometry-compatible elution buffers

• Controls:

  • Pre-immune serum or IgG control

  • YHR131C knockout lysate

  • Input sample quantification

Similar to approaches used in clinical trials for antibodies , optimizing each step in the Co-IP protocol is essential for reliable detection of YHR131C interaction partners.

How should researchers interpret discrepancies in results between different YHR131C antibodies?

When different YHR131C antibodies produce inconsistent results, systematic investigation is necessary:

• Epitope analysis:

  • Map the exact epitopes recognized by each antibody

  • Determine if epitopes might be masked in certain contexts

  • Consider accessibility in native vs. denatured conditions

• Cross-reactivity assessment:

  • Test each antibody against YHR131C knockout samples

  • Perform peptide competition assays

  • Consider similar proteins that might be detected

• Modification sensitivity:

  • Determine if antibodies differentially detect modified forms

  • Test against samples with induced modifications

  • Correlate with mass spectrometry data

• Experimental context:

  • Compare antibody performance across techniques (WB, IP, IF)

  • Evaluate buffer compatibility and optimization needs

  • Consider fixation/preparation effects on epitope availability

• Reconciliation strategies:

  • Use multiple antibodies targeting different regions

  • Correlate with tagged protein detection

  • Implement orthogonal validation approaches

This systematic approach to resolving discrepancies resembles strategies used in clinical antibody development , where multiple verification methods strengthen confidence in results.

What are common pitfalls when working with antibodies against hypothetical proteins like YHR131C?

When working with antibodies against hypothetical proteins like YHR131C, researchers should be aware of these common challenges:

• Expression level uncertainties:

  • Unknown abundance complicates sensitivity requirements

  • Expression may be condition-dependent or transient

  • Possible requirement for enrichment before detection

• Validation limitations:

  • Lack of characterized knockout phenotypes

  • Limited information on expected localization

  • Few reference datasets for comparison

• Specificity concerns:

  • Potential cross-reactivity with related yeast proteins

  • Non-specific binding to abundant cellular components

  • Batch-to-batch variation in antibody performance

• Technical challenges:

  • Optimization of fixation/permeabilization for yeast cells

  • Cell wall interference with antibody penetration

  • Autofluorescence from yeast vacuoles in microscopy

• Data interpretation complexities:

  • Difficulty distinguishing specific from non-specific signals

  • Limited reference data for pattern recognition

  • Challenges in functional interpretation of positive results

Addressing these challenges requires rigorous controls and validation steps similar to those used in developing antibodies against other targets , with additional considerations for the hypothetical nature of YHR131C.

How can researchers determine if their YHR131C antibody is detecting the correct protein?

Confirming that YHR131C antibodies detect the intended target requires multiple validation approaches:

• Genetic validation:

  • Compare signal in wild-type vs. YHR131C deletion strains

  • Test in strains with upregulated YHR131C expression

  • Use strains with epitope-tagged YHR131C for co-detection

• Biochemical confirmation:

  • Mass spectrometry analysis of immunoprecipitated proteins

  • Detection of recombinant YHR131C at predicted molecular weight

  • Peptide competition assays with immunizing peptides

• Orthogonal detection methods:

  • Compare antibody results with GFP-fusion localization

  • Correlate with RNA expression data

  • Validate using alternative antibodies against different epitopes

• Technical controls:

  • Pre-immune serum comparison

  • Secondary antibody-only controls

  • Cross-adsorption against related proteins

Stringent validation using multiple independent methods, similar to approaches used in developing antibodies against tuberculosis biomarkers , provides confidence that the detected protein is indeed YHR131C.